These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 35892165)

  • 1. Plasma circulating cell-free MYCN gene: A noninvasive and prominent recurrence monitoring indicator of neuroblastoma.
    Liang Y; Liu Y; Zhang P; Zhang M; Du B; Cheng W; Yu Z; Li L; Wang H; Hou G; Zhang X; Zhang W
    Cancer Rep (Hoboken); 2023 Feb; 6(2):e1688. PubMed ID: 35892165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual isothermal amplification all-in-one approach for rapid and highly sensitive quantification of plasma circulating MYCN gene of neuroblastoma.
    Liang Y; Wang Q; Zhang X; Zhang M; Du B; Cheng W; Wang H; Li L; Hou G; Zhang W
    Anal Biochem; 2022 Dec; 658():114922. PubMed ID: 36162447
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of the plasma MYCN/NAGK ratio to detect MYCN amplification in patients with neuroblastoma.
    Su Y; Wang L; Zhao Q; Yue Z; Zhao W; Wang X; Duan C; Jin M; Zhang D; Chen S; Yin J; Qiu L; Cheng X; Xu Z; Ma X
    Mol Oncol; 2020 Nov; 14(11):2884-2893. PubMed ID: 32896084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of MYCN amplification in neuroblastoma using serum DNA and real-time quantitative polymerase chain reaction.
    Gotoh T; Hosoi H; Iehara T; Kuwahara Y; Osone S; Tsuchiya K; Ohira M; Nakagawara A; Kuroda H; Sugimoto T
    J Clin Oncol; 2005 Aug; 23(22):5205-10. PubMed ID: 16051962
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implications of a slight increase in the gene dosage of MYCN in neuroblastoma determined using quantitative PCR.
    Souzaki R; Tajiri T; Higashi M; Kinoshita Y; Tanaka S; Kohashi K; Tsuneyoshi M; Taguchi T
    Pediatr Surg Int; 2008 Oct; 24(10):1095-100. PubMed ID: 18726105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in MYCN expression in human neuroblastoma cell lines following cisplatin treatment may not be related to MYCN copy numbers.
    Prochazka P; Hrabeta J; Vicha A; Cipro S; Stejskalova E; Musil Z; Vodicka P; Eckschlager T
    Oncol Rep; 2013 Jun; 29(6):2415-21. PubMed ID: 23563570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of MYCN Amplification in Serum DNA Using Conventional Polymerase Chain Reaction.
    Ma Y; Lee JW; Park SJ; Yi ES; Choi YB; Yoo KH; Sung KW; Koo HH
    J Korean Med Sci; 2016 Sep; 31(9):1392-6. PubMed ID: 27510381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.
    Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E
    Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of MYCN expression in human neuroblastoma cells.
    Jacobs JF; van Bokhoven H; van Leeuwen FN; Hulsbergen-van de Kaa CA; de Vries IJ; Adema GJ; Hoogerbrugge PM; de Brouwer AP
    BMC Cancer; 2009 Jul; 9():239. PubMed ID: 19615087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
    Paffhausen T; Schwab M; Westermann F
    Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binomial mitotic segregation of MYCN-carrying double minutes in neuroblastoma illustrates the role of randomness in oncogene amplification.
    Lundberg G; Rosengren AH; Håkanson U; Stewénius H; Jin Y; Stewénius Y; Påhlman S; Gisselsson D
    PLoS One; 2008 Aug; 3(8):e3099. PubMed ID: 18769732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microarray data analysis of neuroblastoma: Expression of SOX2 downregulates the expression of MYCN.
    Bao J; Qin L; Cui L; Wang X; Meng Q; Zhu L; Zhang S
    Mol Med Rep; 2015 Nov; 12(5):6867-72. PubMed ID: 26398570
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
    Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
    Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human embryonic stem cell-derived neural crest model unveils CD55 as a cancer stem cell regulator for therapeutic targeting in MYCN-amplified neuroblastoma.
    Weng Z; Lin J; He J; Gao L; Lin S; Tsang LL; Zhang H; He X; Wang G; Yang X; Zhou H; Zhao H; Li G; Zou L; Jiang X
    Neuro Oncol; 2022 Jun; 24(6):872-885. PubMed ID: 34655293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dihydropyrimidinase-like protein 3 expression is negatively regulated by MYCN and associated with clinical outcome in neuroblastoma.
    Tan F; Wahdan-Alaswad R; Yan S; Thiele CJ; Li Z
    Cancer Sci; 2013 Dec; 104(12):1586-92. PubMed ID: 24011394
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
    Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
    Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating methylated-DCR2 gene in serum as an indicator of prognosis and therapeutic efficacy in patients with MYCN nonamplified neuroblastoma.
    Yagyu S; Gotoh T; Iehara T; Miyachi M; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tamura S; Tsuchiya K; Imamura T; Misawa-Furihata A; Sugimoto T; Sawada T; Hosoi H
    Clin Cancer Res; 2008 Nov; 14(21):7011-9. PubMed ID: 18980997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN-regulated microRNAs repress estrogen receptor-alpha (ESR1) expression and neuronal differentiation in human neuroblastoma.
    Lovén J; Zinin N; Wahlström T; Müller I; Brodin P; Fredlund E; Ribacke U; Pivarcsi A; Påhlman S; Henriksson M
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1553-8. PubMed ID: 20080637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.